Fig. 6: CRSP8 knockdown enhanced the antitumor effect of cisplatin and epirubicin in thyroid cancer cells.
From: CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation
A–H The sensitivity of thyroid cancer cells to cisplatin or epirubicin treatment at different concentrations and different treatment time points were detected by MTT assay when CRSP8 was silenced or overexpressed. I–J The IC50 values of cisplatin and epirubicin for cell viability inhibition in cells treated with CRSP8 siRNAs or overexpression plasmids. K Western blot analysis of CRSP8, RAD51, and γH2AX expression in thyroid cancer cells following CRSP8 knockdown or overexpression. The data represent the mean ± SD of three independent experiments, and the level of significance was indicated by ***P < 0.001, **P < 0.01. DDP: cisplatin; EPI: epirubicin.
